<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101124171</journal-id>
<journal-id journal-id-type="pubmed-jr-id">29776</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Rev Drug Discov</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat Rev Drug Discov</journal-id>
<journal-title-group>
<journal-title>Nature reviews. Drug discovery</journal-title>
</journal-title-group>
<issn pub-type="ppub">1474-1776</issn>
<issn pub-type="epub">1474-1784</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27980341</article-id>
<article-id pub-id-type="pmc">6416143</article-id>
<article-id pub-id-type="doi">10.1038/nrd.2016.245</article-id>
<article-id pub-id-type="manuscript">NIHMS1013963</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Induced pluripotent stem cell technology: a decade of progress</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Yanhong</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Inoue</surname>
<given-names>Haruhisa</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Joseph C.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamanaka</surname>
<given-names>Shinya</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd, Duarte, CA 91010.</aff>
<aff id="A2"><label>2</label>Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho Shogoin Sakyo-ku Kyoto 606-8507, Japan.</aff>
<aff id="A3"><label>3</label>Stanford Cardiovascular Institute, 265 Campus Drive, Rm G1120B, Stanford, CA 94305-5454.</aff>
<aff id="A4"><label>4</label>Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho Shogoin Sakyo-ku Kyoto 606-8507, Japan.</aff>
<aff id="A5"><label>5</label>Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA</aff>
<author-notes>
<corresp id="CR1">Correspondence should be addressed to Y.S. or H.I. <email>yshi@coh.org</email>; <email>haruhisa@cira.kyotou.ac.jp</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P51">Conflict of Interest</p>
<p id="P52">J.C.W. is a co-founder of Stem Cell Theranostics. S.Y. is a scientific advisor of iPS Academia Japan without salary. The other authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>3</month>
<year>2019</year>
</pub-date>
<volume>16</volume>
<issue>2</issue>
<fpage>115</fpage>
<lpage>130</lpage>
<!--elocation-id from pubmed: 10.1038/nrd.2016.245-->
<abstract id="ABS1">
<p id="P2">Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modeling, drug discovery, and cell therapy development. Novel pathological mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline, and the first clinical trial using human iPSC-derived products has been initiated. In particular, the combination of human iPSC technology with recent developments in gene editing and three-dimensional organoids makes iPSC-based platforms even more powerful in each area of their application, including precision medicine. In this overview, we will discuss the progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, in light of the remaining challenges and the emerging opportunities in the field.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>